Oncology Flashcards

1
Q

PSA screening recommendations

A

Age - offer PSA testing every 2 yrs from 50-69
FHx
- one first degree relative 2.5-3x risk - from >45yrs
- 3x first degree relatives - from > 40 yrs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Prostate cancer investigations

A

Indicated if elevated PSA +/- abnormal DRE

MRI prostate
Multifocal core biopsy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Features suspicious of metastatic prostate cancer

A

PSA > 100ng/dl
Distribution of metastatic disease - sclerotic bone metastases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Prostate management options

A

Localised
- prostatectomy
- radiotherapy

Advanced disease
- hormonal therapy/bilateral orchiectomy
- chemotherapy
- supportive therapy –> RTx, bisphosphonates, palliative care

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

MOA of androgen deprivation therapy

A

ADT –> reduce GnRH –> reduce LH –> reduce testicular testosterone production

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Side effects of ADT

A

Vasomotor symptoms
Reduced libido
Bone density loss
Muscle mass loss
Cardiovascular risk factors
Estrogen deficiency - gynaeocomastia, hot flushes
Testosterone deficiency - erectile dysfunction, diabetes, muscle weakness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Relationship between testosterone and estradiol

A

Testosterone converts to estrogen via CYP19/aromatase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Chemotherapy for prostate cancer

A

Taxanes - docetaxel, cabazitaxel

Used in combination with ADT for “high volume” disease, visceral metastases, multiple bone metastases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

MOA of taxane chemotherapy

A

Interferes with microtubule growth, causing cell arrest in G2/M phase
Inactivates bcl-2 –> apoptosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Side effects of taxane chemotherapy

A

Hair loss
N+V
Pancytopenia
Mucositis/diarrhoea
Lethargy
Fluid retention
Hypersensitivity reactions
Myalgias and arthralgias
Peripheral neuropathy
Nail changes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Examples of direct androgen receptor antagonist

A

Enzalutamide
Apalutamide
Darolutamide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Examples of androgen biosynthesis inhibitor (17a-hydroxylase)

A

Abiraterone
Blocks synthesis of testosterone in adrenal gland via inhibition of 17a-hydroxylase and C17,20-lyase activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Mechanism of cortisol inhibition of abiraterone

A

Abiraterone (androgen biosynthesis inhibitor via 17a hydroxylase)

ACTH rises in response to increase in deoxycortisterone (due to decrease in 17OH-progesterone) –> leads to decrease in cortisol (thus should have mandatory concurrent steroids)

Also results in increased shunting, causing excess mineralocorticoid (hyperaldosteronism)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Side effects of direct androgen receptor antagonists

A

Fatigue
Cognitive impairment
Falls
Seizures
Rash

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Side effects of androgen biosynthesis inhibitor

A

Cardiac toxicity
Hypertension
Concurrent steroids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Bone protection methods for prostate cancer

A

Calcium and vitamin D supplementation
Weight bearing exercise
DEXA scan monitoring
High risk - denosumab, ZA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Common complications of prostate cancer

A

Acute urinary retention
Bilateral ureteric obstruction
Spinal cord compression
Pancytopenia from BM infiltration
Bilateral lower limb lymphoedema secondary to pelvic obstruction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Genetic defects in prostate cancer

A

Aberrations in ~1/3rd of pts
BRCA2 most common alteration seen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Testicular cancer classification

A

Pure seminoma - AFP not elevated
Non seminoma/mixed germ cell tumour - often elevated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Testicular cancer epidemiology

A

Most commonly seen in 25-40 yrs
Median age at diagnosis is 33 yrs
Increased risk with cryptorchidism
5 yr relative survival ~98%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Tumour markers for prostate cancer

A

AFP, beta HCG, LDH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Role of AFP and beta HCG

A

Useful for surveillance/follow up
Associated with prognosis and used to guide treatment in advanced disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Treatment of testicular cancer

A

Localised disease
- Orchiectomy
- Surveillance

Metastatic/advanced disease
- Chemotherapy (Bleomycin, etoposide, platinum)
- Resection of residual masses

Relapsed/refractory disease
- Second line chemotherapy
- High dose chemo and mini-autografts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Toxicities associated with chemotherapy for testicular cancer

A

Pancytopenia, alopecia, lethargy

Cisplatin
- Hearing impairment
- Tinnitus
- Peripheral neuropathy
- Renal impairment

Bleomycin
- Hypersensitivity
- Pneumonitis/lung toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Risk factors for CRC
Excess body weight Low levels of physical activity High consumption of processed meat and EtOH Low fibre consumption Cigarette smoking IBD - Pancolitis > left sided colitis - CD FHx Familial cancer syndromes
26
Common heritable syndromes for CRC
HNPCC/Lynch syndrome FAP
27
Genetic factors for CRC
High penetrance genes - APC, biallelic MUTYH, BRCA1/2, PALB2, CDKN2A, TP53 Moderate penetrance genes - monoallelic MUTYH, APC allele, p.I1307K, CHEK 2
28
Characteristics of HNPCC/Lynch syndrome
Autosomal dominant, high penetrance Mean age - 48 yrs Defect in DNA mismatch repair (MMR) genes Phenotype - 60-70%: R sided/proximal colonic tumours - 10% synchronous or metachronous tumours - Polyps may be present, can overlap with AFAP - Extracolonic tumours - endometrial, ovarian, stomach, SB, hepatobiliary, brain, renal, pelvis/ureter
29
Pts at risk of HNPCC
Amsterdam criteria - >/ 3 relatives with Lunch associated Ca (of which one is a 1st degree relative) - Lynch associated Ca involving at least 2 generations - >/ 1 diagnosed before 50 yrs Bethesda criteria - CRC Dx < 50 yrs - Synchronous, metachronous or other Lynch associated Ca, regardless of age - CRC with MSI-like histology (TILs, mucinous/signet ring, poorly differentiated) - >/ 1st degree relatives with Lynch associated Ca with 1 diagnosed < 50y/o - CRC diagnosed in >/ 2 1st degree relatives with Lynch associated Ca
30
BRAFV600E mutation and Lynch syndrome
If BRAFV600E ABSENT - would rule out Lynch syndrome
31
MMR genes
MLH1, MSH2, MSH6, PMS2
32
MAPK pathway
EGFR > RAS > BRAF > MEK > ERK > cell growth and differentiation
33
BRAF mutation positive CRC
Poor prognosis Poor response to standard chemo Requires BRAF inhibitor with EGFR inhibitor (due to upregulation of EGFR in pathway)
34
FAP features
Germline mutation of APC gene on chromosome 5 FAP - Average age of polyposis 16 yrs (100-1000s), CRC by 45 yrs if untreated --> screening from 10-15 yrs AFAP - < 100 polyps, CRC 54 yrs --> screening at 25 yrs
35
Colonoscopy timing for Lynch syndrome
1-2 yrly colonoscopies from age 25 yrs or 5 years younger than youngest affected case
36
Colonoscopy timing for APC mutation
Classic FAP Surveillance from 10-15 yrs Once adenoma detected, annual colonoscopy until total colectomy and ileorectal anastomosis
37
Examples and side effects of fluoropyrimidines
5-FU Capecitabine S/E: Hand foot syndrome Diarrhoea/mucositis Haematological/myelosuppression Coronary artery spasm Acute coronary events
38
SEs of oxaliplatin
N+V, diarrhoea Lethargy Haematological/myelosuppression Peripheral neuropathy - cumulative Cold sensitivity/dysaesthesias Laryngopharyngeal dysaesthesia Hypersensitivity reaction
39
Factors to consider for treatment of CRC
L vs R sided primary RAS/RAF status MMR status If metachronous/relapsed
40
Chemotherapy for metastatic CRC
Single agent: - Fluoropyrimidines (5FU or capecitabine) - Irinotecan - TAS102 Doublet: - Fluoropyrimidines with addition of oxaliplatin (FOLFOX/CAPOX) or irinotecan (FOLFIRI/CAPIRI) Triplet: 5FU, oxiliplatin and irinotecan (FOLFOXIRI)
41
MOA and SE of irinotecan
Topoisomerase inhibitor Metabolised by UGT1A1*28 genetic polymorphisms S/E: Diarrhoea, anticholinergic effects, myelosuppression, alopecia
42
Targeted therapies for mCRC
VEGF inhibitors - bevacizumab (used regardless of RAS/RAF status, location) EGFR inhibitor - cetuximab/panitumumab (only in RAS WT tumours, left sided primary)
43
Side effects of VEGF inhibitors
HTN Delayed wound healing Intestinal perforation/fistula formation Proteinuria/nephrotic syndrome Increased risk of bleeding/haemorrhage Increased risk of arterial thrombotic events
44
Mechanisms of resistance for EGFR inhibitors
Downstream mutations of MAPK pathway - KRAS/NRAS mutations - BRAF mutations
45
S/E of EGFR inhibitors
- Cutaneous - Skin - xerosis (dry skin), paronychia/fissures - Diarrhoea - Hypomagnesaemia - Infusion reactions
46
Use of pembrolizumab in mCRC
Used in MSI high (or dMMR) mCRC MSI --> increases presence of neoantigens with increase TILs --> over expression of PD-1 and PDL-1
47
Oesophageal cancer classification and prognosis
Classified - adenocarcinoma or SCC Poor prognosis due to aggressive course and metastatic disease
48
Treatment for oesophageal cancer
Neoadjuvant chemoradiation Chemotherapy - 5FU or capecitabine - Platinum drugs - cisplatin, carboplatin, oxaplatin - Irinotecan - Taxanes - paclitaxel - TAS102 Targeted egents - HER2 positive - trastuzumab - Ramicirumab Immunotherapy - Nivolumab (for PDL1 positive)
49
Management of pancreatic cancer
Resection for early stage pancreatic cancer - Whipple's procedure Neoadjuvant/Adjuvant therapy with chemotherapy (FOLFIRINOX or gemcitabine based therapy) +/- chemoradiation or stereotactic therapy
50
MOA of gemcitabine + adverse effects
Pyrimidine analog chemotherapy Pneumonitis - potent radiosensitiser - synergistically worsens gemcitabine-induced lung toxicity
51
Clinical features of carcinoid syndrome
Cutaneous flushing Venous telangiectasia Secretory diarrhoea Bronchospasm Cardiac valvular lesions in right side of heart (inactivation of humoral substances by lungs protects left heart)
52
Risk factor for breast cancer
Female gender Increasing age Older age at first birth Oestrogen EtOH Family history
53
Genetic factors involved in breast cancer
BRCA 1/2 STK11 (Peutz-Jeghers) PTEN (PTEN hamartoma tumour syndrome/Cowden) CDH1 (Hereditary diffuse gastric Ca) MSH1/ML1/MSH6/PMS2/EPCAM (Lynch) PALB2 CHEK2 ATM
54
High risk factors of breast Ca
Multiples relatives with breast or ovarian Ca > 1 primary Ca Vertical transmission FHx of rare malignancies Epithelial ovarian Ca
55
Screening of breast Ca
6 monthly breast examination Annual mammogram from 40 (or 5 yrs younger than relative) MRI breast (particularly if pre-menopausal)
56
Investigations of breast cancer
Mammogram +/- US FNA/Core biopsy Referral to breast surgeon
57
Poor prognostic features of breast Ca
Positive axillary lymph nodes Increasing size Higher grade Negative hormone receptors HER 2+ve Younger age Lymphovascular invasion
58
Treatment of early stage breast Ca
Surgery - Wide local excision - Total mastectomy (Neo)adjuvant chemo Adjuvant RTx Adjuvant hormone therapy Adjuvant trastuzumab
59
Indications of hormonal therapy for breast cancer
All ER+/PR+ breast cancer Pre-menopausal: SERM (tamoxifen, toremifene), GnRH agonist Post-menopausal: Aromatase inhibitors (anastrozole, letrozole, exemestane)
60
MOA and adverse events of SERMs
Antagonist on oestrogen receptor in breast tissue or cancer (However agonist effects on some receptors i.e. bones, uterus, liver) Increases BMD in post-menopausal women Risk of VTE, uterine Ca
61
MOA and adverse events of aromatase inhibitors
Blocks DHEA --> reduces oestrogen Reduces BMD Arthralgias No increased risk of VTE, uterine Ca
62
Indications for and MOA of trastuzumab
HER2+ve tumour Given with chemotherapy Mechanism of action: Targets HER2/neu (c-erbB2) tyrosine kinase receptor → ↓ of HER2 initiated cellular signaling and ↑ antibody-dependent cytotoxicity → ↓ tumor growth
63
Adverse effects of trastuzumab
Cardiomyopathy (usually reversible, however should have TTE prior) GI side effects
64
Indications of chemotherapy for breast cancer
- Tumor size > 2 cm - Triple-negative breast cancer and tumor size ≥ 0.5 cm - HER-2 positive breast cancer and tumor size > 1 cm - Positive lymph nodes - Aggressive tumor histology
65
Treatment for ER+/HER2- breast Ca
First line - CDK4/6 inhibitor + hormonal therapy (chemo if rapid response required) CDK4/6 inhibitor - ribociclib, abemaciclib, palbociclib
66
Treatment for HER2+ breast Ca
1st line - trastuzumab/pertuzumab/taxane 2nd line - Trastuzumab emtansine (T-DM1/Kadcyla) - conjugate with antimicrotubule agent Trastuzumab deruxtecan (T-DXed) - conjugate with topoisomerase inhibitor 3rd line - Lapatinib
67
MOA of Pertuzumab
Monoclonal Ab, used in combo with trastuzumab Binds to dimerisation domain of HER2 receptor but also prevents binding with itself or other EGFR
68
Treatment for BRCA+ve cancer
PARP inhibitor Repairs DNA damage
69
Clinical presentation of Pancoast tumour
Superior sulcus tumour Usually NSCLC Pain in shoulder/neuropathic arm pain Horner's syndrome (though rare) Wasting hand muscles
70
Clinical features of lung cancer
Cough Haemoptysis Chest pain Dyspnoea - bronchial obstruction, pleural effusion Hoarse voice SVC obstruction Extrathoracic mets Hypercalcaemia SIADH (especially SCLC) Hypertrophic pulmonary arthropathy
71
Features of SCLC
Early to metastasise, high mitotic rate Classically bulky lymphadenopathy Very chemo and radiosensitive Almost all cases are smokers Doesn't cause clubbing Paraneoplastic syndromes
72
Treatment of SCLC
Chemoimmunotherapy 1st line - Atezolizumab (PD-L1) + carboplatin + etoposide 2nd line - Topotecan/irinotecan - Lurbinectedin - Cyclophosphamide/doxorubicin/vincristine
73
Features of mesothelioma
Asbestos + tobacco related Long latency (30-40 yrs)
74
Treatment for mesothelioma
Generally incurable - Radical treatment - extrapleural pneumonectomy - Platinum + pemetrexed (folate antimetabolite) - Dual immunotherapy: nivolumab and ipilimumab
75
Staging principles
Stage 1: small tumour Stage 2: large tumour or small tumour with nodal involvement Stage 3: very large tumour, invasion into mediastinum, ipsilateral lung nodules (3a) or contralateral hilar nodes (3b) Stage 4: pleural effusion, contralateral lung nodules, distant mets
76
Driver mutations in lung adenocarcinoma
EGFR ALK rearrangement ROS1 fusion BRAF ERBB2 MET RET NTRK KRAS
77
EGFR inhibitor examples
1st gen: Gefitinib, erlotinib 2nd gen: Afatinib 3rd gen: Osimertinib
78
Adverse effects of EGFR inhibitors
Acne like rash Diarrhoea Nausea Pulmonary fibrosis
79
Mechanism of action of EGFR inhibitor resistance
Due to T790M resistance mutation Use of osimertinib highly active against T790M
80
Targeted therapy for ALK gene rearrangement
ALK phosphorylation inhibitors 1st gen: crizotinib 2nd gen: ceritinib 3rd gen: alectinib (better CNS penetration), lorlatinib, brigitinib
81
Targeted therapy for ROS-1 fusion
Responsive to ALK inhibitors - Crizotinib, lorlatinib, entrectinib
82
Treatment for KRAS +ve lung adenocarcinomas
More common in smokers Chemo as first line Sotorasib (KRAS G12C inhibitor) as 2nd line therapyT
83
Treatment for NSCLC with no driver mutations
PD-L1 score If < 50% - chemoimmunotherapy --> platinum doublet + PD-L1 inhibitor If > 50% --> single agent PD-L1 inhibitor
84
Tumour markers
CEA - colon cancer CA125 - ovarian cancer CA15.3 - breast cancer CA19.9 - breast cancer AFP - germ cell tumours/hepatocellular cancer PSA - prostate cancer
85
Predictive marker of melanoma
Breslow depth of lesion and presence or absence of ulceration
86
Clinical signs of melanoma
Asymmetry Borders (uneven vs even) Colour Diameter Enlargement or evolution
87
Melanoma subtypes
Radial growth phase - Superficial spreading - Lentigo maligna - Acral lentiginous Vertical growth phase - Nodular
88
Clinical features looked at in early nodular melanoma
Symmetry Raised Colour Firmness Progressive growth
89
Major determinants of outcome for stage III melanoma
Number of metastatic lymph nodes Tumour burden Presence of absence of ulceration of primary melanoma Presence or absence of satellite or in-transit metastasis
90
Pathway activated in melanoma
- MAPK cascade activated in almost all types of melanoma – 80% due to mutations in NRAS or BRAF genes - BRAF mutations present in 40-60% of metastatic melanomas - More common in cutaneous melanomas without chronic sun damage (mutations in c-kit more common in CSD) - With treatments, disease related to BRAF mutations has significantly improved
91
Management of stage III melanoma
Stage 3A - observation Stage 3B/3C/3D/resected stage 4 - adjuvant therapies - BRAF mutant: Dabrafenib and trametinib (BRAF and MEK inhibitor) - Anti-PD1 for all patients: Nivolumab/Pembolizumab
92
Treatment of stage IV melanoma
Targeted therapy with immunotherapy (PDL1 inhibitor, BRAF mutant targeted therapy) Surgical resection of metastasis
93
BRAF targeted therapy
Dabrafenib Trametinib
94
Molecular biology profile of melanoma
Intermittent sun exposure: - BRAF - NRAS - PTEN - AKT - p16 Chronic sun exposure: - KIT - CDK4 - Cyclin D1 Acral exposure: - NRAS - KIT - CDK4 - Cyclin 4 Mucosal exposure - CDK4 - KIT
95
BRAF inhibitors
Vemurafenib (selective V600E mutations) Dabrafenib (inhibits all V600 mutations) Encorafenib (inhibits all V600 mutations)
96
MEK inhibitors
Cobimetinib Trametinib Binimetinib
97
cKIT inhibitors
Imatinib
98
Management of activating BRAF mutations
BRAF kinase inhibitor (e.g., vemurafenib) is used in metastatic or unresectable melanomas that have the BRAF V600E mutation (substitution of glutamic acid in place of valine at amino acid position 600 caused by activating mutations in the BRAF gene)
99
BRAF inhibitor adverse events
Cutaneous SCC and keratoacanthoma Hyperkeratosis Skin papilloma Hand foot syndrome Alopecia Photosensitivity and sunburn
100
MOA of CTLA-4
Receptor expressed on activated helper T cells and CTLs Inhibits T cell activation and proliferation - Binds to B7 molecule on APCs surface with higher affinity than CD28 - Puts break on T cell proliferation CTLA4 ligands (CD80 and CD86)
101
Immune related adverse events with CTLA-4 inhibitors
Rash Colitis Arthritis Hepatitis Hypo/hyperthyroidism Pneumonitis
102
Management of IRAEs
Grade III/IV --> generally reversible and can be treated with standard anti-inflammatory therapies i.e. corticosteroids Grade IV --> prolonged steroid taper and TNF blockade with infliximab or prolonged bowel rest with TPN
103
Anti-PD1 MOA
Restores anti-tumour T cell function Enhances pre-existing T cell response Increases cytokine production
104
Anti-CTLA4 MOA
Induces de novo anti-tumour T cell responses Enables adaptation to evolving tumour Promotes emergence of memory T cells Causes compensatory increase in tumour PD-L1
105
PD-1 protein
T cell coinhibitory receptor structurally similar to CTLA-4 but with distinct biologic function and ligand specificity Two known ligands, PD-L1 and PD-L2 Selectively expressed on many tumours and on cells within tumour microenvironment in response to inflammatory stimuli
106
VEGF inhibitor side effects
HTN - predictive marker Reversible posterior leukoencephalopathy Proteinuria/renal dysfunction Haemorrhage
107
mTOR inhibitors toxicity
Oral ulceration - mouth ulcers, stomatitis Rash Fatigue HTN Hand and foot syndrome Diarrhoea Infections Pneumonitis
108
TKIs rash predictive marker
Higher grade rash, higher probability of response
109
VEGF receptor TKIs
Pazopanib Sunitinib Sorafenib Cabozantinib Tivozanib Axitinib Lenvatinib
110
mTOR inhibitors
Everolimus Temsirolimus
111
Anti-VEGF antibodies
Bevacizumab
112
RCC paraneoplastic syndrome
- Secondary hypercortisolism: due to ectopic ACTH release - Secondary polycythemia: due to ectopic erythropoietin (EPO) secretion - Hypertension: due to the release of renin - Hypercalcemia: due to the release of PTHrP (parathyroid hormone-related protein) - Leukemoid reaction: due to bone marrow stimulation - Limbic encephalitis: Memory loss, Psychosis, Depression
113
114
Features of Li Fraumeni syndrome
Mutation of p53 tumour suppression gene BLAST 53 - Breast cancer/brain tumour - leukaemia/lymphoma - adrenocortical carcinoma - sarcoma - Tp53